SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice-Reference-Cited by-同舟云学术

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

Published:2017-06 Issue: Volume:20 Page:137-149
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Xu Liang,Nagata Naoto^ORCID,Nagashimada Mayumi,Zhuge Fen,Ni Yinhua,Chen Guanliang,Mayoux Eric,Kaneko Shuichi,Ota Tsuguhito

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference46 articles.

1. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states;Badman;Cell Metab.,2007

2. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion;Bonner;Nat. Med.,2015

3. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity;Brestoff;Nature,2015

4. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch;Cohen;Cell,2014

5. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (dio) rats;Devenny;Obesity,2012

Cited by 353 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inibidores de SGLT2 e inflamassoma NLRP3: alvo potencial na doença renal do diabetes;Brazilian Journal of Nephrology;2024-12

2. SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease;Brazilian Journal of Nephrology;2024-12

3. Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits;Cellular Signalling;2024-10

4. Empagliflozin add‐on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: An open‐label, single‐center, pilot clinical trial;Journal of General and Family Medicine;2024-09-08

5. SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation;Cell Metabolism;2024-09